UY24789A1 - Amidas inhibidoras de la secrecion de apo b/mtp - Google Patents

Amidas inhibidoras de la secrecion de apo b/mtp

Info

Publication number
UY24789A1
UY24789A1 UY24789A UY24789A UY24789A1 UY 24789 A1 UY24789 A1 UY 24789A1 UY 24789 A UY24789 A UY 24789A UY 24789 A UY24789 A UY 24789A UY 24789 A1 UY24789 A1 UY 24789A1
Authority
UY
Uruguay
Prior art keywords
inhibitors
formula
pharmaceutically acceptable
compound
hmg
Prior art date
Application number
UY24789A
Other languages
English (en)
Inventor
George Joseph Quallich
George Chang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY24789A1 publication Critical patent/UY24789A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de la fórmula I (com por ejemplo: {6-[(4'-trifluorometilbifenil-2-caronil)-amino]-3,4-dihidro-1H-isoquinolin-2-il}-acetico) o a los estereosiómeros, sales farmacéuticamente aceptables e hidratos de los mismos, donde G selecciona entre, fenilo o un anillo heterociclico, CH2CN, un compuesto de fórmula ll, un alquilo o perfluoroalquilo donde cada uno puede estar sustituido. Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz de un compuesto de fórmula l o un estereoisómero, sal farmacéuticamente aceptable o hidrato del mismo, junto con un vehiculo o diluyente farmacéuticamente aceptable. Dicha compuesto de la invención son inhibidores de Apo B/MTP y son útiles en el tratamiento de diversos trastornos y fecciones tales como la aterosclerosis, la pancreatitis, la obesidad, la hipercolesterolemia, la hipertrigliceridemia, la hiperlipidemia y la diabetes. También son útiles junto con otros agente farmacéuticos que incluyen inhibidores de la biosintesis de colesterol e inhibidores de la absorción de colesterol, especialmente inhibidores de la HMG-CoA reductasa e inhibidores de la HMG-CoA sintasa; inhibidores de la expresión génica de la HMG-CoA redictasa, inhibidores de CETP, complejantes de ácidos biliares, fibratos; inhibidores de la absorción del colesterol, inhibidores de ACAT, etc. Esta invención tamién esta dirigida a intermedios y procedimientos útiles en la preparación de compuestos de fórmula l.
UY24789A 1996-11-27 1997-11-25 Amidas inhibidoras de la secrecion de apo b/mtp UY24789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3230796P 1996-11-27 1996-11-27

Publications (1)

Publication Number Publication Date
UY24789A1 true UY24789A1 (es) 2000-09-29

Family

ID=21864233

Family Applications (1)

Application Number Title Priority Date Filing Date
UY24789A UY24789A1 (es) 1996-11-27 1997-11-25 Amidas inhibidoras de la secrecion de apo b/mtp

Country Status (34)

Country Link
US (1) US6121283A (es)
EP (1) EP0944602A1 (es)
JP (1) JP3270764B2 (es)
KR (1) KR100334567B1 (es)
CN (2) CN1238764A (es)
AP (1) AP804A (es)
AR (1) AR010309A1 (es)
AU (1) AU716151B2 (es)
BG (2) BG108830A (es)
BR (1) BR9714364A (es)
CA (1) CA2272719C (es)
CZ (1) CZ292160B6 (es)
DZ (1) DZ2358A1 (es)
EA (1) EA001539B1 (es)
GT (1) GT199700122A (es)
HN (1) HN1997000144A (es)
HR (1) HRP970642A2 (es)
ID (1) ID18995A (es)
IL (1) IL129744A0 (es)
IS (1) IS5040A (es)
MA (1) MA26451A1 (es)
NO (1) NO312760B1 (es)
NZ (1) NZ335162A (es)
OA (1) OA11050A (es)
PA (1) PA8441601A1 (es)
PE (1) PE17199A1 (es)
SK (1) SK65499A3 (es)
TN (1) TNSN97193A1 (es)
TR (1) TR199901180T2 (es)
TW (1) TW502023B (es)
UY (1) UY24789A1 (es)
WO (1) WO1998023593A1 (es)
YU (1) YU23499A (es)
ZA (1) ZA9710641B (es)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5919795A (en) * 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
AU4543899A (en) 1998-06-08 1999-12-30 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
EA200100428A1 (ru) 1998-10-08 2001-10-22 Смитклайн Бичам Плс Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты)
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
NZ512536A (en) * 1998-12-23 2003-11-28 G Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
WO2000038725A1 (en) * 1998-12-23 2000-07-06 G.D. Searle Llc Combinations for cardiovascular indications
DE19929012A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln
DE19929031A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
AU6824700A (en) * 1999-07-20 2001-02-05 Novartis Ag Organic compounds
IL139449A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Use of apo b secretion/mtp inhibitors
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
IL139450A0 (en) * 1999-11-10 2001-11-25 Pfizer Prod Inc Methods of administering apo b-secretion/mtp inhibitors
CA2324800A1 (en) * 1999-11-10 2001-05-10 Mary Anne Hickman Use of apo b secretion/mtp inhibitors
ES2240420T3 (es) * 2000-01-18 2005-10-16 Novartis Ag Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b.
JP4009460B2 (ja) * 2000-03-14 2007-11-14 アクテリオン ファマシューティカルズ リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
WO2001077077A1 (en) * 2000-04-10 2001-10-18 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
GB0013346D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
WO2002014277A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes de biphenylcarboxamidoisoindoline, procedes de preparation de ceux-ci et produits intermediaires destines a la synthese de ceux-ci
WO2002014276A1 (fr) * 2000-08-10 2002-02-21 Tanabe Seiyaku Co., Ltd. Composes a base de benzoylaminoisoindoline, leurs procedes de preparation et produits intermediaires utilises dans leur synthese
WO2002020009A1 (fr) * 2000-09-01 2002-03-14 Sankyo Company, Limited Compositions medicales
JO2654B1 (en) 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
US20040058903A1 (en) * 2000-10-05 2004-03-25 Hisashi Takasugi Benzamide compounds as apo b secretion inhibitors
JO2409B1 (en) 2000-11-21 2007-06-17 شركة جانسين فارماسوتيكا ان. في Second-phenyl carboxy amides are useful as lipid-lowering agents
JP2004532856A (ja) * 2001-04-30 2004-10-28 藤沢薬品工業株式会社 アポリポタンパク質ｂ阻害剤としてのビアリールカルボキサミド化合物
CA2450957A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
AU2002322585A1 (en) * 2001-07-20 2003-03-03 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2003013516A1 (en) * 2001-08-10 2003-02-20 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2003045921A1 (en) * 2001-11-28 2003-06-05 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic amide compounds as apolipoprotein b inhibitors
CA2472028C (en) * 2002-02-01 2010-03-30 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
SG165154A1 (en) * 2002-02-28 2010-10-28 Japan Tobacco Inc Ester compound and medical use thereof
US7241774B2 (en) * 2002-03-13 2007-07-10 University Of Tennessee Research Foundation Substituted tetrahydroisoquinoline compounds, methods of making, and their use
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
JP2006516028A (ja) * 2002-12-20 2006-06-15 ファイザー・プロダクツ・インク ミクロソームトリグリセリド輸送タンパク質阻害剤
WO2004056777A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
KR20050110017A (ko) 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
EP1669345A4 (en) * 2003-08-29 2008-02-20 Japan Tobacco Inc ESTER DERIVATIVE AND MEDICAL USE THEREOF
WO2005118548A1 (en) 2004-03-01 2005-12-15 Actelion Pharmaceuticals Ltd Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
JP2006249022A (ja) 2005-03-11 2006-09-21 Sumitomo Chemical Co Ltd ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法
BRPI0607555A2 (pt) 2005-04-19 2009-09-15 Surface Logix Inc inibidores da proteìna microssomal de transferência de triglicirideo e secreção de apo-b
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA3042781C (en) 2006-04-03 2021-10-19 Roche Innovation Center Copenhagen A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100813A1 (ru) * 2006-04-03 2012-06-29 Сантарис Фарма А/С Фармацевтическая композиция
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
WO2007143164A1 (en) * 2006-06-02 2007-12-13 San Diego State University Research Foundation Compositions and methods for ameliorating hyperlipidemia
US20100216864A1 (en) * 2006-10-09 2010-08-26 Ellen Marie Straarup RNA Antagonist Compounds for the Modulation of PCSK9
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
JO2653B1 (en) 2006-10-24 2012-06-17 شركة جانسين فارماسوتيكا ان. في Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB
EP2076487B1 (en) 2006-10-24 2010-05-26 Janssen Pharmaceutica N.V. Mtp inhibiting tetrahydro-naphthalene-1-carboxylic acid derivatives
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
WO2008075949A1 (en) * 2006-12-20 2008-06-26 Friesland Brands B.V. Modulation of human microsomal triglyceride transfer protein (mtp or mttp) gene expression by food-grade/ingested dietary microorganisms
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
US8580756B2 (en) * 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
CA2681406A1 (en) * 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
EP2162451A4 (en) * 2007-06-25 2012-04-18 Neurogen Corp PIPERAZINYL-OXOALKYL-TETRAHYDRO-BETA-CARBOLINE AND RELATED ANALOGUE
WO2009027527A2 (en) * 2007-08-30 2009-03-05 Santaris Pharma A/S Rna antagonist compounds for the modulation of fabp4/ap2
ES2463665T3 (es) * 2007-10-04 2014-05-28 Stella Aps Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C
ES2575131T3 (es) 2007-12-03 2016-06-24 Obe Therapy Biotechnology Inhibidores boropéptidos de enteropeptidasa y sus usos en tratamientos de obesidad, sobrepeso y/o enfermedades asociadas con un metabolismo anormal de la grasa
JP2011506466A (ja) 2007-12-11 2011-03-03 株式会社サイトパスファインダー カルボキサミド化合物ならびにケモカイン受容体アゴニストとしてのそれらの使用
US20090197947A1 (en) * 2008-02-01 2009-08-06 The Research Foundation Of State University Of New York Medicaments and methods for lowering plasma lipid levels and screening drugs
US8361980B2 (en) * 2008-03-07 2013-01-29 Santaris Pharma A/S Pharmaceutical compositions for treatment of microRNA related diseases
ES2541442T3 (es) 2008-08-01 2015-07-20 Roche Innovation Center Copenhagen A/S Modulación mediada por microARN de factores estimulantes de colonias
EP2421970B1 (en) * 2009-04-24 2016-09-07 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon
US8563528B2 (en) 2009-07-21 2013-10-22 Santaris Pharma A/S Antisense oligomers targeting PCSK9
JP2016516804A (ja) 2013-04-17 2016-06-09 ファイザー・インク 心血管疾患を治療するためのｎ−ピペリジン−３−イルベンズアミド誘導体
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
WO2015065595A1 (en) 2013-10-30 2015-05-07 Trustees Of Dartmouth College Method for selectively inhibiting acat1 in the treatment of obesity, metabolic syndrome, and atherosclerosis
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2016064970A1 (en) * 2014-10-22 2016-04-28 The Board Of Regents Of The University Of Texas System Small-molecule inhibitors targeting discoidin domain receptor 1 and uses thereof
EP3911648A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
CN113292493A (zh) * 2021-06-23 2021-08-24 上海立科化学科技有限公司 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
US5595872A (en) * 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996040640A1 (en) * 1995-06-07 1996-12-19 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION

Also Published As

Publication number Publication date
NO312760B1 (no) 2002-07-01
YU23499A (sh) 2001-07-10
BR9714364A (pt) 2000-03-21
AU4634797A (en) 1998-06-22
AP9701145A0 (en) 1998-01-31
KR100334567B1 (ko) 2002-05-03
TR199901180T2 (xx) 1999-08-23
BG103434A (en) 2000-07-31
JP2000505810A (ja) 2000-05-16
EA001539B1 (ru) 2001-04-23
DZ2358A1 (fr) 2002-12-28
NZ335162A (en) 2000-01-28
CA2272719A1 (en) 1998-06-04
NO992525D0 (no) 1999-05-26
US6121283A (en) 2000-09-19
TNSN97193A1 (fr) 2005-03-15
IL129744A0 (en) 2000-02-29
SK65499A3 (en) 2001-05-10
NO992525L (no) 1999-05-26
HN1997000144A (es) 1997-12-16
PA8441601A1 (es) 2000-05-24
EA199900416A1 (ru) 1999-12-29
AU716151B2 (en) 2000-02-17
JP3270764B2 (ja) 2002-04-02
HRP970642A2 (en) 1998-10-31
PE17199A1 (es) 1999-02-19
WO1998023593A1 (en) 1998-06-04
CZ292160B6 (cs) 2003-08-13
BG108830A (bg) 2005-10-31
ID18995A (id) 1998-05-28
GT199700122A (es) 1999-05-19
ZA9710641B (en) 1999-05-26
CA2272719C (en) 2002-10-01
EP0944602A1 (en) 1999-09-29
TW502023B (en) 2002-09-11
CN1238764A (zh) 1999-12-15
AP804A (en) 2000-01-28
AR010309A1 (es) 2000-06-07
IS5040A (is) 1999-04-30
OA11050A (en) 2002-03-07
KR20000057269A (ko) 2000-09-15
MA26451A1 (fr) 2004-12-20
CN1380289A (zh) 2002-11-20

Similar Documents

Publication Publication Date Title
UY24789A1 (es) Amidas inhibidoras de la secrecion de apo b/mtp
US6506797B1 (en) Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) α
TW200800947A (en) Trisubstituted amine compound
US20050288337A1 (en) Novel compounds
NO319781B1 (no) 4-Aminosubstituerte 2-substituerte 1,2,3,4-tetrahydrokinoliner som CETP inhibitorer, anvendelse derav samt farmasoytisk sammensetning og sett.
EP1472215A2 (en) (oxime)carbamoyl fatty acid amide hydrolase inhibitors
UY25131A1 (es) Derivados de ácidos ariloxiarilsulfonilamino hidroxamicos
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
HRP20110805T1 (hr) Homo- i heterociklički spojevi prikladni kao cetp inhibitori
DE69027794D1 (de) N-Phenyl-N-(4-piperidinyl)-amide, verwendbar als Analgetika
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
US20050234096A1 (en) Tetrahydroisoquinoline derivatives
DE69231445D1 (de) Triazole enthaltende antifungizide mittel
HK1044955A1 (en) Heterocyclic compounds, intermediates thereof and elastase inhibitors.
HRP20000460A2 (en) Matrix metalloprotease inhibitors
HK1078854A1 (en) Method for producing a 3,5-dihydroxy-6-heptenoate
US9657006B2 (en) Macrocyclic factor VIIa inhibitors
DE69528978D1 (de) Lactamverbindungen als Inhibitoren der Cholesterin-Esterase
MXPA05008601A (es) Derivados de benzamida como agonistas de oxitocina y antagonistas de vasopresina.
US6552073B1 (en) Compounds and methods of treating cell proliferative diseases
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
CA3108046A1 (en) Benzene derivative
AU2013209344B2 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
ECSP972325A (es) Amidas inhibidoras de la secrecion de apo b/mtp
CO4650034A1 (es) Amidas inhibidoras de la secrecion de apo b/mtp

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20091028